10-Q 1 kzr-10q_20190331.htm 10-Q kzr-10q_20190331.htm

75

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2019

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number: 001-38542

 

Kezar Life Sciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

47-3366145

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

4000 Shoreline Court, Suite 300

South San Francisco, CA, 94080

(650) 822-5600

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

  

Accelerated filer

 

Non-accelerated filer

 

  

  

Smaller reporting company

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, $0.001 par value

KZR

The Nasdaq Stock Market LLC

As of May 2, 2019, the registrant had 19,119,421 shares of common stock, $0.001 par value per share, outstanding.

 

 

 

 


Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements (Unaudited)

2

 

Condensed Consolidated Balance Sheets

2

 

Condensed Consolidated Statements of Operations

3

 

Condensed Consolidated Statements of Comprehensive Loss

4

 

Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

5

 

Condensed Consolidated Statements of Cash Flows

6

 

Notes to Unaudited Condensed Consolidated Financial Statements

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

17

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

23

Item 4.

Controls and Procedures

23

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

24

Item 1A.

Risk Factors

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

59

Item 3.

Defaults Upon Senior Securities

59

Item 4.

Mine Safety Disclosures

59

Item 5.

Other Information

59

Item 6.

Exhibits

60

 

 

 

 

 

i


 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements. In some cases, you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “potential,” “project,” “plan,” “expect,” “seek,” “should,” “target” or similar expressions, or the negative or plural of these words or expressions. These forward-looking statements include statements concerning the following:   

 

our plans to develop and commercialize our product candidates;

 

the initiation, timing, progress and expected results of our current and future clinical trials and our research and development programs;

 

our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

 

our ability to successfully acquire or in-license additional product candidates or other technology on reasonable terms;

 

our ability to maintain and establish collaborations or strategic relationships or obtain additional funding;

 

the timing and likelihood of obtaining regulatory approval of our current and future product candidates;

 

our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates;

 

our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources;

 

the implementation of our business model and strategic plans for our business and product candidates;

 

the scope of protection we are able to establish and maintain for intellectual property rights and the duration of our patent rights covering our product candidates;

 

developments or disputes concerning our intellectual property or other proprietary rights;

 

the scalability and commercial viability of our manufacturing methods and processes;

 

our expectations regarding government and third-party payor coverage and reimbursement;

 

our ability to compete in the markets for our product candidates;

 

the impact of government laws and regulations;

 

developments relating to our competitors and our industry; and

 

the factors that may impact our financial results.

These statements are only current predictions and are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in greater detail under the heading “Risk Factors” and elsewhere in this report. You should not rely upon forward-looking statements as predictions of future events.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements in this report, whether as a result of new information, future events or otherwise, after the date of this report.

Unless the context otherwise requires, the terms “Kezar,” “Kezar Life Sciences,” “the Company,” “we,” “us,” “our” and similar references in this Quarterly Report on Form 10-Q refer to Kezar Life Sciences, Inc. and our wholly owned Australian subsidiary, Kezar Life Sciences Australia Pty Ltd.

 


 

1


PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

KEZAR LIFE SCIENCES, INC.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

 

 

March 31, 2019

 

 

December 31, 2018

 

 

 

(Unaudited)

 

 

(Note 2)

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

18,470

 

 

$

24,182

 

Marketable securities

 

 

82,664

 

 

 

83,250

 

Prepaid expenses

 

 

1,664

 

 

 

1,884

 

Other current assets

 

 

991

 

 

 

489

 

Total current assets

 

 

103,789

 

 

 

109,805

 

Property and equipment, net

 

 

4,846

 

 

 

4,595

 

Operating lease right-of-use asset

 

 

4,139

 

 

 

 

Other assets

 

 

282

 

 

 

282

 

Total assets

 

$

113,056

 

 

$

114,682

 

Liabilities and Stockholders' Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

1,448

 

 

$

193

 

Accrued liabilities

 

 

2,406

 

 

 

2,678

 

Operating lease liabilities, current

 

 

804

 

 

 

 

Deferred rent, current

 

 

 

 

 

354

 

Other liabilities, current

 

 

100

 

 

 

112

 

Total current liabilities

 

 

4,758

 

 

 

3,337

 

Operating lease liabilities, noncurrent

 

 

6,153

 

 

 

 

Deferred rent

 

 

 

 

 

2,548

 

Total liabilities

 

 

10,911

 

 

 

5,885

 

Stockholders' equity:

 

 

 

 

 

 

 

 

Common stock, $0.001 par value, 125,000,000 shares authorized as of March 31,

   2019 and December 31, 2018; 19,118,421 and 19,114,421 shares issued and

   outstanding as of March 31, 2019 and December 31, 2018, respectively

 

 

19

 

 

 

19

 

Preferred stock, $0.001 par value, 10,000,000 shares authorized as of

   March 31, 2019 and December 31, 2018; zero shares issued and

   outstanding as of March 31, 2019 and December 31, 2018

 

 

 

 

 

 

Additional paid-in capital

 

 

159,093

 

 

 

158,176

 

Accumulated other comprehensive loss

 

 

(130

)

 

 

(203

)

Accumulated deficit

 

 

(56,837

)

 

 

(49,195

)

Total stockholders' equity

 

 

102,145

 

 

 

108,797

 

Total liabilities and stockholders' equity

 

$

113,056

 

 

$

114,682

 

 

See accompanying notes to the unaudited interim condensed consolidated financial statements

 

 

2


KEZAR LIFE SCIENCES, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

(In thousands, except share and per share amounts)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2019

 

 

2018

 

Operating expenses:

 

 

 

 

 

 

 

 

Research and development

 

$

5,927

 

 

$

3,572

 

General and administrative

 

 

2,382

 

 

 

1,514

 

Total operating expenses

 

 

8,309

 

 

 

5,086

 

Loss from operations

 

 

(8,309

)

 

 

(5,086

)

Interest income

 

 

667

 

 

 

139

 

Net loss

 

$

(7,642

)

 

$

(4,947

)

Net loss per common share, basic and diluted

 

$

(0.40

)

 

$

(6.53

)

Weighted-average shares used to compute net loss per common

   share, basic and diluted

 

 

19,042,524

 

 

 

757,399

 

 

See accompanying notes to the unaudited interim condensed consolidated financial statements

 

3


KEZAR LIFE SCIENCES, INC.

Condensed Consolidated Statements of Comprehensive Loss

(Unaudited)

(In thousands)

 

 

 

Three Months Ended

 

 

 

 

March 31,

 

 

 

 

2019

 

 

2018

 

 

Net loss

 

$

(7,642

)

 

$

(4,947

)

 

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments

 

 

8

 

 

 

(23

)

 

Unrealized gain on marketable securities

 

 

65

 

 

 

 

 

Total other comprehensive income (loss), net of tax

 

 

73

 

 

 

(23

)

 

Comprehensive loss

 

$

(7,569

)

 

$

(4,970

)

 

 

See accompanying notes to the unaudited interim condensed consolidated financial statements

 

4


KEZAR LIFE SCIENCES, INC.

Condensed Consolidated Statement of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)

(Unaudited)

(In thousands, except share amounts)

 

 

 

REDEEMABLE

CONVERTIBLE

PREFERRED STOCK

 

 

 

COMMON STOCK

 

 

ADDITIONAL

PAID-IN

 

 

ACCUMULATED

OTHER

COMPREHENSIVE

 

 

ACCUMULATED

 

 

TOTAL

STOCKHOLDERS'

 

 

 

SHARES

 

 

AMOUNTS

 

 

 

SHARES

 

 

AMOUNTS

 

 

CAPITAL

 

 

INCOME (LOSS)

 

 

DEFICIT

 

 

EQUITY

 

Balance at December 31, 2018

 

 

 

 

 

 

 

 

 

19,114,421

 

 

$

19

 

 

$

158,176

 

 

$

(203

)

 

$

(49,195

)

 

$

108,797

 

Issuance of common stock upon exercise of stock options

 

 

 

 

 

 

 

 

 

4,000

 

 

 

 

 

 

4

 

 

 

 

 

 

 

 

 

4

 

Vesting related to common shares issued pursuant to early exercises

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

12

 

 

 

 

 

 

 

 

 

12

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

901

 

 

 

 

 

 

 

 

 

901

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

73

 

 

 

 

 

 

73

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,642

)

 

 

(7,642

)

Balance at March 31, 2019

 

 

-

 

 

$

-

 

 

 

 

19,118,421

 

 

$

19

 

 

$

159,093

 

 

$

(130

)

 

$

(56,837

)

 

$

102,145

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

REDEEMABLE

CONVERTIBLE

PREFERRED STOCK

 

 

 

COMMON STOCK

 

 

ADDITIONAL

PAID-IN

 

 

ACCUMULATED

OTHER

COMPREHENSIVE

 

 

ACCUMULATED

 

 

TOTAL

STOCKHOLDERS'

 

 

 

SHARES

 

 

AMOUNTS

 

 

 

SHARES

 

 

AMOUNTS

 

 

CAPITAL

 

 

INCOME (LOSS)

 

 

DEFICIT

 

 

EQUITY (DEFICIT)

 

Balance at December 31, 2017

 

 

12,263,126

 

 

$

77,931

 

 

 

 

948,578

 

 

$

1

 

 

$

451

 

 

$

(111

)

 

$

(26,028

)

 

$

(25,687

)

Issuance of common stock upon exercise of stock options, net of amount related to early exercised options

 

 

 

 

 

 

 

 

 

109,818

 

 

 

 

 

 

25

 

 

 

 

 

 

 

 

 

25

 

Vesting related to common shares issued pursuant to early exercises

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

17

 

 

 

 

 

 

 

 

 

17

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

126

 

 

 

 

 

 

 

 

 

126

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(23

)

 

 

 

 

 

(23

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,947

)

 

 

(4,947

)

Balance at March 31, 2018

 

 

12,263,126

 

 

$

77,931

 

 

 

 

1,058,396

 

 

$

1

 

 

$

619

 

 

$

(134

)

 

$

(30,975

)

 

$

(30,489

)

 

See accompanying notes to the unaudited interim condensed consolidated financial statements

 

5


KEZAR LIFE SCIENCES, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2019

 

 

2018

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net loss

 

$

(7,642

)

 

$

(4,947

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

303

 

 

 

87

 

Stock-based compensation

 

 

901

 

 

 

126

 

Amortization of premiums and discounts on marketable securities

 

 

(359

)

 

 

 

Loss on disposal of property and equipment

 

 

 

 

 

97

 

Changes in operating assets and liabilities

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

 

(282

)

 

 

(641

)

Other assets

 

 

 

 

 

39

 

Accounts payable and accrued liabilities

 

 

560

 

 

 

1,028

 

Other liabilities, current

 

 

 

 

 

149

 

Deferred rent

 

 

 

 

 

296

 

Operating lease liabilities

 

 

(181

)

 

 

 

Net cash used in operating activities

 

 

(6,700

)

 

 

(3,766

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(34

)

 

 

(195

)

Purchases of marketable securities

 

 

(35,936

)

 

 

 

Maturities of marketable securities

 

 

36,946

 

 

 

 

Net cash provided by (used in) investing activities

 

 

976

 

 

 

(195

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Proceeds from the exercise of stock options

 

 

4

 

 

 

25

 

Net cash provided by financing activities

 

 

4

 

 

 

25

 

Effect of exchange rate changes on cash and cash equivalents and restricted cash

 

 

8

 

 

 

(12

)

Net decrease in cash, cash equivalents and restricted cash

 

 

(5,712

)

 

 

(3,948

)

Cash, cash equivalents and restricted cash at the beginning of period

 

 

24,182

 

 

 

51,046

 

Cash, cash equivalents and restricted cash at the end of period

 

$

18,470

 

 

$

47,098

 

Supplemental disclosures of noncash investing and financing information:

 

 

 

 

 

 

 

 

Reclassification of employee stock liability to equity upon vesting

 

$

12

 

 

$

17

 

Addition of tenant improvement paid by landlord

 

$

 

 

$

2,054

 

Purchase of property and equipment in accounts payable

 

$

423

 

 

$

21

 

Deferred offering costs in accrued liabilities

 

$

 

 

$

1,300

 

 

See accompanying notes to the unaudited interim condensed consolidated financial statements 

 

 

 

6


 

Kezar Life Sciences, Inc

Notes to Unaudited Condensed Consolidated Financial Statements

1. Organization and Description of the Business

Description of Business

Kezar Life Sciences, Inc. (the “Company,” “we,” “us,” or “our”) was incorporated in the state of Delaware in February 2015 and commenced operations in June 2015. The Company is a clinical-stage biotechnology company, discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The Company’s principal operations are in South San Francisco, California, and it operates in one segment.

Liquidity

Since commencing operations in mid-2015, substantially all of the Company’s efforts have been focused on research, development, and the advancement of the Company’s lead product candidate, KZR-616. The Company’s ultimate success depends on the outcome of the ongoing research and development activities. The Company has not yet generated product sales and as a result has experienced operating losses since inception and had an accumulated deficit of $56.8 million as of March 31, 2019. The Company expects to incur additional losses in the future to conduct research and development and will need to raise additional capital to fully implement management’s business plan. The Company intends to raise such capital through the issuance of additional equity, and potentially through borrowings, strategic alliances with partner companies and other licensing transactions. However, if such financing is not available at adequate levels, the Company may need to reevaluate its operating plans. Management believes that its existing cash, cash equivalents and marketable securities will be sufficient to fund the Company’s cash requirements for at least 12 months following the issuance of these financial statements.

2. Summary of Significant Accounting Policies

Significant Accounting Policies

The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2018 and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 26, 2019 and except for the adoption of the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), there have been no material changes during the three months ended March 31, 2019.

Basis of Presentation and Consolidation

The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) and include the Company’s accounts and those of its wholly owned Australian subsidiary, Kezar Life Sciences Australia Pty Ltd, which is a proprietary company limited by shares. All intercompany balances and transactions have been eliminated upon consolidation.

The condensed consolidated balance sheet at December 31, 2018 has been derived from the audited consolidated financial statements at that date, but does not include all information and footnotes required by GAAP for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2018.

Unaudited Interim Condensed Consolidated Financial Statements

The accompanying financial information as of March 31, 2019 is unaudited. The condensed consolidated financial statements included in this report reflect all adjustments (consisting only of normal recurring adjustments) that our management considers necessary for the fair statement of the results of operations for the interim periods covered and of our financial condition at the date of the interim balance sheet. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. The results for interim periods are not necessarily indicative of the results for the entire year or any other interim period. The accompanying condensed consolidated financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018, filed with the SEC on March 26, 2019.

 

7


 

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant items subject to such estimates and assumptions include the useful lives of fixed assets, stock-based compensation, and accrued research and development costs. Management bases its estimates on historical experience and on various other market-specific relevant assumptions that management believes to be reasonable under the circumstances. Actual results may differ from those estimates.

Cash and Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash equivalents consist of corporate debt securities and highly liquid money market funds.

Restricted cash at January 1, 2018 consisted of approximately a $13,000 deposit at the bank held as collateral for the Company’s credit card program. The collateral requirement was removed and released in May 2018.

Marketable Securities

All marketable securities have been classified as “available-for-sale” in accordance with the Company’s investment policy and cash management strategy. Short-term marketable securities mature within one-year from the balance sheet date. Investments in marketable securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders’ deficit until realized or until a determination is made that an other-than-temporary decline in market value has occurred. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion, together with interest on securities, are included in interest income on the Company’s condensed consolidated statements of operations.

Leases

At lease commencement, the Company records a lease liability based on the present value of lease payments over the expected lease term. The Company calculates the present value of lease payments using the discount rate implicit in the lease, unless that rate cannot be readily determined. In that case, the Company uses its incremental borrowing rate, which is the rate of interest that the Company would have to pay to borrow on a collateralized basis an amount equal to the lease payments over the expected lease term. The Company records a corresponding right-of-use (“ROU”) lease asset based on the lease liability, adjusted for any lease incentives received and any initial direct costs paid to the lessor prior to the lease commencement date.

After lease commencement, the Company measures its leases as follows: (i) the lease liability based on the present value of the remaining lease payments using the discount rate determined at lease commencement; and (ii) the ROU lease asset based on the remeasured lease liability, adjusted for any unamortized lease incentives received, any unamortized initial direct costs and the cumulative difference between rent expense and amounts paid under the lease agreement. Any lease incentives received and any initial direct costs are amortized on a straight-line basis over the expected lease term. Rent expense is recorded on a straight-line basis over the expected lease term.

Accounting Pronouncements Adopted in 2019

Leases (Topic 842)

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). ASU 2016-02 increases transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and requires disclosing key information about leasing arrangements. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements, which provides entities the option to initially apply the transition provisions of ASU 2016-02 at its adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption.

The Company adopted the new standard on January 1, 2019 and used the effective date as its date of initial application. Consequently, financial information will not be restated and the disclosures required under the new standard will not be provided for dates and periods before January 1, 2019. The Company elected the package of transition practical expedients that allows the Company not to reassess the lease classification for any expired or existing contracts, whether initial direct costs were incurred, or whether any expired or existing contracts contained leases.

 

8


 

This standard had a material effect on the Company’s financial statements. The most significant effects relate to (1) the recognition of new ROU asset and lease liabilities on the balance sheet for the operating lease for its headquarters at 4000 Shoreline Court, South San Francisco; and (2) providing significant new disclosures about its leasing activities.

The following table discloses the impact on our balance sheet upon adoption (in thousands):

 

 

January 1, 2019

 

 

December 31, 2018

 

Operating lease ROU asset

 

$

4,236

 

 

$

 

Operating lease liabilities, current

 

 

774

 

 

 

 

Operating lease liabilities, noncurrent

 

 

6,364

 

 

 

 

Deferred rent, current

 

 

 

 

 

354

 

Deferred rent, noncurrent

 

 

 

 

 

2,548

 

 

The new standard also provides practical expedients for an entity’s ongoing accounting. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company did not elect the practical expedient to not separate lease and non-lease components for all of its leases.

Stock Compensation (Topic 718)

In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718). ASU 2018-07 simplifies the accounting for nonemployee share-based payment transactions. This ASU is effective for public entities for interim and annual reporting periods beginning after December 15, 2018. The Company adopted the new standard on January 1, 2019 and determined that it did not have a material impact on the Company’s financial statements.

New Accounting Pronouncements Not Yet Adopted

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326). ASU 2016-13 requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for us beginning in the first quarter of 2020 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted beginning in the first quarter of 2019. The Company is currently evaluating the potential impact of the adoption of this guidance on its financial statements.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. The amendment of ASU No. 2018-13 removes disclosure requirements from Topic 820 in the areas of (1) the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; (2) the policy for timing of transfers between levels, and (3) the valuation processes for Level 3 fair value measurements. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. The Company is currently evaluating the effect the new guidance will have on its consolidated financial statements.

3. Fair Value Measurements

Financial assets and liabilities are recorded at fair value. The carrying amount of certain financial instruments, including cash and cash equivalents, restricted cash, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities. Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

 

9


 

Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.

We determine the fair value of Level 1 assets using quoted prices in active markets for identical assets. We review trading activity and pricing for Level 2 investments as of each measurement date. Level 2 inputs, which are obtained from various third-party data providers, represent quoted prices for similar assets in active markets and were derived from observable market data, or, if not directly observable, were derived from or corroborated by other observable market data. There were no transfers between Level 1 and Level 2 securities in the periods presented.

In certain cases, where there is limited activity or less transparency around inputs to valuation, securities are classified as Level 3 within the valuation hierarchy. The Company does not have any assets or liabilities measured using Level 3 inputs as of March 31, 2019 or December 31, 2018.

The following table summarizes our financial assets measured at fair value on a recurring basis and classified under the appropriate level of the fair value hierarchy as described above (in thousands):

 

 

 

March 31, 2019

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

18,349

 

 

$

18,349

 

 

$

 

 

$

 

U.S. Treasury securities

 

 

13,695

 

 

 

13,695

 

 

 

 

 

 

 

Commercial paper

 

 

19,357

 

 

 

 

 

 

19,357

 

 

 

 

Corporate debt securities

 

 

20,538

 

 

 

 

 

 

20,538

 

 

 

 

Government agency bonds

 

 

29,075

 

 

 

 

 

 

29,075

 

 

 

 

Total

 

$

101,014

 

 

$

32,044

 

 

$

68,970

 

 

$

 

 

 

 

December 31, 2018

 

 

 

Total

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

Financial Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

23,156

 

 

$

23,156

 

 

$

 

 

$

 

U.S. Treasury securities

 

 

25,692

 

 

 

25,692

 

 

 

 

 

 

 

Commercial paper

 

 

19,190

 

 

 

 

 

 

19,190

 

 

 

 

Corporate debt securities

 

 

20,451

 

 

 

 

 

 

20,451

 

 

 

 

Government agency bonds

 

 

17,917

 

 

 

 

 

 

17,917

 

 

 

 

Total

 

$

106,406

 

 

$

48,848

 

 

$

57,558

 

 

$

 

 

 

 

10


 

4. Available-for-Sale Securities

The following table is a summary of available-for-sale securities recorded in cash and cash equivalents or marketable securities in our condensed consolidated balance sheets (in thousands):

 

 

 

March 31, 2019

 

 

 

Amortized Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair Value

 

Financial Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

 

18,349

 

 

 

 

 

 

 

 

 

18,349

 

U.S. Treasury securities

 

 

13,691

 

 

 

4

 

 

 

 

 

 

13,695

 

Commercial paper

 

 

19,342

 

 

 

15

 

 

 

 

 

 

19,357

 

Corporate debt securities

 

 

20,521

 

 

 

17

 

 

 

 

 

 

20,538

 

Government agency bonds

 

 

29,066

 

 

 

9

 

 

 

 

 

 

29,075

 

Total

 

$

100,969

 

 

$

45

 

 

$

 

 

$

101,014

 

 

 

 

December 31, 2018

 

 

 

Amortized Cost

 

 

Unrealized

Gains

 

 

Unrealized

Losses

 

 

Fair Value

 

Financial Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

$

23,156

 

 

$

 

 

$

 

 

$

23,156

 

U.S. Treasury securities

 

 

25,698

 

 

 

 

 

 

(6

)

 

 

25,692

 

Commercial paper

 

 

19,203

 

 

 

 

 

 

(13

)

 

 

19,190

 

Corporate debt securities

 

 

20,449

 

 

 

4

 

 

 

(2

)

 

 

20,451

 

Government agency bonds

 

 

17,921

 

 

 

 

 

 

(4

)

 

 

17,917

 

Total

 

$

106,427

 

 

$

4

 

 

$

(25

)

 

$

106,406

 

 

As of March 31, 2019, the amortized cost and estimated fair value of the Company’s available-for-sale securities by contractual maturity are shown below (in thousands):

 

 

 

Amortized

 

 

Estimated

 

 

 

Cost

 

 

Fair Value

 

Marketable securities maturing:

 

 

 

 

 

 

 

 

In one year or less

 

$

82,619

 

 

$

82,664

 

Total marketable securities

 

$

82,619

 

 

$

82,664

 

 

5. Balance Sheet Components

Property and Equipment, Net

Property and equipment consists of the following (in thousands):

 

 

 

March 31,

2019

 

 

December 31,

2018

 

Leasehold improvements

 

$

3,268

 

 

$

3,268

 

Furniture, laboratory and office equipment

 

 

2,489

 

 

 

2,043

 

Computer equipment

 

 

230

 

 

 

219

 

Total property and equipment

 

 

5,987

 

 

 

5,530

 

Less accumulated depreciation and amortization

 

 

(1,141

)

 

 

(935

)

Property and equipment, net

 

$

4,846

 

 

$

4,595

 

 

Depreciation expense was $0.2 million and $0.1 million for the three months ended March 31, 2019 and 2018, respectively.

 

 

11


 

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

 

 

March 31,

2019

 

 

December 31,

2018

 

Accrued preclinical and research costs

 

$

1,128

 

 

$

1,146

 

Accrued clinical costs

 

 

528

 

 

 

434

 

Accrued employee-related costs

 

 

554

 

 

 

736

 

Accrued professional services

 

 

90

 

 

 

138

 

Other

 

 

106

 

 

 

224

 

Total accrued liabilities

 

$

2,406

 

 

$

2,678

 

 

6. Operating Lease

In August 2017, the Company entered into a lease agreement to lease 24,357 square feet of combination laboratory and office space in South San Francisco, California. This lease expires in February 2025.

The contractually specified minimum rent and annual rent increases for the operating lease are included in the measurement of the ROU asset and related lease liabilities. Under the lease arrangement, we may be required to pay directly, or reimburse the lessor for real estate taxes, insurance, utilities, maintenance and other operating costs. Such amounts are generally variable and therefore not included in the measurement of the ROU asset and related lease liability but are instead recognized as variable lease expense in our Condensed Consolidated Statements of Operations when they are incurred. The option to extend the lease was not recognized as part of the Company’s lease liability and ROU asset.

Because the rate implicit in the lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments. The Company recorded lease liabilities and ROU asset for its office lease based on the present value of lease payments over the expected lease term.

Information related to the Company’s ROU asset and related lease liabilities were as follows (in thousands):

 

 

For three months ended March 31, 2019

 

Cash paid for operating lease liabilities

$

181

 

Remaining lease term

5.92 years

 

Discount rate

 

10

%

 

 

 

 

Maturities of lease liabilities as of March 31, 2019 were as follows:

 

 

 

2019

$

1,095

 

2020

 

1,497

 

2021

 

1,542

 

2022

 

1,588

 

2023

 

1,635

 

2024

 

1,684

 

Thereafter

 

282

 

Total undiscounted lease payments

 

9,323

 

Less: imputed interest

 

(2,366

)

Total lease liabilities

$

6,957

 

 

 

 

 

Operating lease liabilities, current

 

804

 

Operating lease liabilities, noncurrent

 

6,153

 

Total operating lease liabilities

$

6,957

 

 

12


 

Future minimum lease payments are as follows as of December 31, 2018 (in thousands):

 

Year ending December 31:

 

 

 

 

2019

 

$

1,453

 

2020

 

 

1,497

 

2021

 

 

1,542

 

2022

 

 

1,588

 

2023

 

 

1,635

 

Thereafter

 

 

1,966

 

Total future minimum lease payments

 

$

9,681

 

 

7. Stock-Based Compensation

Stock Incentive Plans

2018 Equity Incentive Plan

In June 2018, the Company’s board of directors adopted and its stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”), which became effective as of June 20, 2018, at which point no further grants will be made under the 2015 Equity Incentive Plan (the “2015 Plan”) described below. Under the 2018 Plan, the Company may grant incentive stock options (“ISOs”), nonstatutory stock options (“NSOs”), stock appreciation rights, restricted stock awards, restricted stock units (“RSUs”) and other stock-based awards for the purchase of that number of shares of common stock. As of March 31, 2019, options to purchase 663,621 shares of common stock and 10,189 RSUs have been granted and 2,179,866 shares were available for future issuance under the 2018 Plan.

Initially, subject to adjustment as provided in the 2018 Plan, the aggregate number of shares of the Company’s common stock that may be issued pursuant to stock awards under the 2018 Plan will not exceed 4,000,000 shares, which is the sum of (i) 1,600,692 shares plus (ii) the number of shares reserved, and remaining available for issuance, under the 2015 Plan at the time the 2018 Plan became effective and (iii) the number of shares subject to stock options or other stock awards granted under the 2015 Plan that expire, terminate are forfeited or otherwise not issued, or are withheld to satisfy a tax withholding obligation in connection with an award or to satisfy a purchase or exercise price of an award (such as upon the expiration or termination of a stock award prior to vesting). The number of shares of the Company’s common stock reserved for issuance under the 2018 Plan will automatically increase on January 1 of each year, beginning on January 1, 2019 and continuing through and including January 1, 2028, by 5% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors. The maximum number of shares that may be issued upon the exercise of ISOs under the 2018 Plan is 12,500,000 shares.

2015 Equity Incentive Plan

The Company’s 2015 Equity Incentive Plan provided for the granting of ISOs and NSOs to employees, directors and consultants at the discretion of the board of directors. The 2015 Plan was terminated as to future awards in June 2018, although it continues to govern the terms of options that remain outstanding under the 2015 Plan.

No additional stock awards will be granted under the 2015 Plan, and all outstanding stock awards granted under the 2015 Plan that are repurchased, forfeited, expire or are cancelled will become available for grant under the 2018 Plan in accordance with its terms.

Options granted under the 2015 Plan expire no later than 10 years from the date of grant. Options granted under the 2015 Plan vest over periods determined by the board of directors, generally over four years. The 2015 Plan allows for early exercise of certain options prior to vesting. Upon termination of employment, the unvested shares are subject to repurchase at the original exercise price. As of March 31, 2019, options to purchase 2,091,845 shares of common stock were outstanding under the 2015 Plan.

2018 Employee Stock Purchase Plan

In June 2018, the Company’s board of directors and its stockholders approved the 2018 Employee Stock Purchase Plan (the “ESPP”), which became effective as of June 20, 2018. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the U.S. Internal Revenue Code of 1986, as amended. The number of shares of common stock initially reserved for issuance under the ESPP was 200,000 shares. The ESPP provides for an annual increase on the first day of each year beginning in 2019 and ending in 2028, in each case subject to the approval of the board of directors, equal to the lesser of (i) 1% of the shares of common stock outstanding on the last day of the prior fiscal year or (ii) 375,000 shares; provided, that prior to the date of any such increase, the board of directors may determine that such increase will be less than the amount set forth in clauses (i) and (ii).

 

13


 

As of March 31, 2019, no shares of common stock had been issued under the ESPP and 391,144 shares remained available for future issuance under the ESPP. The option price per share of common stock to be paid by a participant upon exercise of the participant’s option on the applicable exercise date for an offering period shall be equal to 85% of the lesser of the fair market value of a share of common stock on (a) the applicable grant date or (b) the applicable exercise date. The Board authorized an initial offering beginning on November 16, 2018 and ending on May 15, 2019. Following the end of the initial offering, a new offering will automatically begin on the day that immediately follows the conclusion of the preceding offering.

Stock Option Activity

The following table summarizes activity under the Company’s stock option plan and related information (in thousands, except share and per share amounts):

 

 

 

Number of Options Outstanding

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Term (Years)